Imedex® is an industry leader in providing certified, independent continuing medical education to health care professionals.

May 8, 2017

Chicago, IL
Hyatt Regency Chicago
West Tower, Lobby Level, Crystal Ballroom

The Evolving Therapeutic Armamentarium for IBD: Is Our Target within Reach?

May 8, 2017
Hyatt Regency Chicago
West Tower, Lobby Level, Crystal Ballroom
Chicago, Illinois

6:00 pm – 6:30 pm: Registration and Dinner
6:30 pm – 8:30 pm: Presentations

The therapeutic landscape of IBD has evolved tremendously in the past decade, especially in terms of newer biologics. With the addition and refinement of newer classes of therapeutic biological targets and the emergence of newer treatment goals such as 'mucosal healing' and 'treat to target', patients with ulcerative colitis (UC) and Crohn's disease (CD) have experienced enhanced outcomes and improved quality of life.

However, with the multitude of information and guidelines associated with each class of biologics, healthcare professionals require an expert review of the ever-evolving therapeutic landscape in order to implement the latest treatment options in a day to day clinical practice. Particularly, they need to keep abreast with the plethora of emerging biologics, their novel mechanisms of action (MOA), and use in various patient populations.

To this end, the Evolving Therapeutic Armamentarium for IBD: Is Our Target Within Reach? symposium is designed to provide IBD specialists with expert perspectives on the application of the most relevant translational research, clinical trials, treatment guidelines, and FDA regulations pertaining to newer biologics with the goal of enhancing patient outcomes.


Marla Dubinsky, MD
Icahn School of Medicine at Mount Sinai
New York, New York

Gil Y. Melmed, MD, MS, FACG
Cedars Sinai
Los Angeles, California

Miguel D. Regueiro, MD, AGAF, FACG, FACP
University of Pittsburgh School of Medicine
Pittsburgh, Pennsylvania


Scientific Agenda

Monday, May 8, 2017

6:30 PM

Welcome, pre-activity learner survey
Miguel D. Regueiro, MD, AGAF, FACG, FACP

6:35 PM

Current and evolving therapeutic landscape of IBD
Marla Dubinsky, MD

6:55 PM

Deciphering the signaling mechanisms involved in the future therapeutic management of IBD
Gil Y. Melmed, MD, MS, FACG

7:15 PM

Round table discussion:

Case #1: Role of emerging biologics in UC superimposed with anti-TNF-failure

Case #2: Role of mucosal healing, capsule endoscopy and therapeutic drug monitoring in treating moderate to severe refractory CD

8:15 PM

Closing remarks, and post-activity learner survey

8:30 PM



Continuing Education

Imedex®, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME®) to provide continuing medical education for physicians.

Imedex, LLC designates this live educational activity for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only credit commensurate with the extent of their participation in the activity.

Maintenance of Certification (MOC)

Successful completion of this CME activity enables a participant to earn up to 2.0 MOC points towards the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is Imedex’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC Points.

Who Should Attend

This symposium is designed to meet the educational needs of gastroenterologists, gastroenterology NPs, PAs and nurses, and other healthcare professionals who have a specialty and/or interest in the management of patients with IBD.


After successful completion of this activity, participants will be able to:

      • Analyze pathophysiology of IBD, MOA of drugs with their safety & efficacy profiles 
      • Implement the rational use of current and emerging therapies, with a focus on diverse patient population
      • Interpret pertinent clinical trial data for standard of care and optimal management strategies for IBD



Registration is Complimentary!

Registration for this CME activity is limited to clinicians in practice. For all other professionals, we will be taking stand-by seating onsite based upon seating availability.

Available seating will be based on room capacity. Seating is limited and pre-registration does not guarantee admission, as the room may be overbooked. Early arrival is recommended and seating for clinicians will be first-come first-serve until capacity is met. All other professionals standing by will be seated upon availability.

Clinicians and stand-by professionals must have their DDW badge for entrance.

How To Register: You may register online at or by calling Imedex at +1 (800) 233 0957 (international callers please call +1 (678) 242 0906).  For assistance, please contact Registration confirmations will be issued before the meeting.

Registration Inclusions: Registration includes admittance to all scientific sessions, activity materials, processing of certificates of participation or continuing education credit, and all event functions as specified in the agenda.

Imedex does not accept responsibility for covering travel, accommodation or any other costs incurred by registrants in the rare event that this meeting should be canceled for any reason. Every effort will be made to give reasonable notice in the event of cancellation. The event agenda is subject to change without notice.



Supported by educational grants from AbbVie and Medtronic



11675 Rainwater Drive, Suite 600
Alpharetta, GA 30009, USA
Tel.: +1 (770) 751 7332
Fax: +1 (770) 751 7334

For registration inquiries:
Tel.: +1 (800) 233 0957
Direct: +1 (678) 242 0906
Fax: +1 (678) 242-0870